Revolutionizing Meningioma Management: A Clinical Tool Predicts Tumor Growth and Symptoms
Imagine a world where the most common type of brain tumour, the meningioma, can be predicted with precision. A groundbreaking online tool, developed by the University of Liverpool and The Walton Centre, is transforming this once uncertain scenario into a more manageable and personalized approach to patient care.
The IMPACT tool, launched in 2019, is a clinical marvel that considers a patient's comorbidities, functional status, and tumour imaging characteristics. This comprehensive analysis allows it to predict the risk of tumour progression and the need for treatment with remarkable accuracy. Developed from data of around 400 patients under neurosurgical care, the tool has since been rigorously tested on over 1,200 patients from 33 hospitals across 15 countries, with follow-up periods of up to 15 years.
The results are impressive. Patients can be reliably grouped into low, medium, or high-risk categories for tumour progression. Low-risk patients, with only a 4% chance of needing treatment, can be safely discharged with advice on symptoms to watch for. Medium-risk patients face a 25% risk, while high-risk patients have a 50% chance of progression. Most progression occurs within the first five years, with older or frailer patients being very unlikely to require treatment.
This study, led by Abdurrahman Islim, a neurosurgery registrar at the University of Manchester & Salford Royal Hospital, marks a significant step forward in personalizing care for meningioma patients. For the first time, patients with incidental meningiomas can receive clear answers about their individual risk, avoiding unnecessary scans for some and ensuring timely treatment for others.
Michael Jenkinson, study lead and professor of neurosurgery at the University of Liverpool, emphasizes the importance of testing the IMPACT tool in real-time with patients in clinics and securing funding to integrate it into routine practice. He believes that personalized care will not only benefit patients' health but also lead to cost savings for the NHS and broader economic growth.
Meningiomas, accounting for around 3,500 new cases in the UK annually, are often discovered incidentally during brain scans. While most are harmless, some eventually require surgery or other treatment. Until now, predicting which patients would be affected has been challenging, leading to unnecessary monitoring for some and delayed treatment for others. The IMPACT tool promises to change this, offering a more efficient and effective approach to managing meningiomas.
